Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
Taieb et al.,
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal..,
J. Clin. Med. 2021, doi:10.3390/jcm10132954
Retrospective 926 patients in Senegal, 674 treated with HCQ+AZ, showing significantly higher hospital discharge at day 15 with treatment.
risk of no hospital discharge, 38.7% lower, OR 0.61, p = 0.02, treatment 674, control 252, inverted to make OR<1 favor treatment, multivariate, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Taieb et al., 30 Jun 2021, retrospective, Senegal, peer-reviewed, 29 authors, average treatment delay 6.0 days.
Abstract: Journal of
Clinical Medicine
Article
Hydroxychloroquine and Azithromycin Treatment of
Hospitalized Patients Infected with SARS-CoV-2 in Senegal
from March to October 2020
Fabien Taieb 1, *, Khardiata Diallo Mbaye 2 , Billo Tall 1 , Ndèye Aïssatou Lakhe 2 , Cheikh Talla 1 , Daouda Thioub 2 ,
Amadou Moustapha Ndoye 1 , Daye Ka 2 , Aboubacry Gaye 1 , Viviane Marie-Pierre Cissé Diallo 2 , Ndongo Dia 1 ,
Pape Samba Ba 3 , Mamadou Cissé 1 , Moustapha Diop 3 , Cheikh Tidiane Diagne 1 , Louise Fortes 2,4 ,
Mamadou Diop 1 , Ndèye Maguette Fall 2,5 , Fatoumata Diène Sarr 1 , Margarite Diatta 1 , Mamadou Aliou Barry 1 ,
Aboubakar Sidikh Badiane 2,6 , Abdoulaye Seck 1 , Philippe Dubrous 1 , Ousmane Faye 1 , Inès Vigan-Womas 1 ,
Cheikh Loucoubar 1 , Amadou Alpha Sall 1 and Moussa Seydi 2
1
Citation: Taieb, F.; Mbaye, K.D.; Tall,
2
B.; Lakhe, N.A.; Talla, C.; Thioub, D.;
Ndoye, A.M.; Ka, D.; Gaye, A.; Cissé
Diallo, V.M.-P.; et al.
Hydroxychloroquine and
3
Azithromycin Treatment of
Hospitalized Patients Infected with
4
SARS-CoV-2 in Senegal from March
5
to October 2020. J. Clin. Med. 2021, 10,
Institut Pasteur de Dakar, Dakar BP 220, Senegal; billo.tall@pasteur.sn (B.T.); ctalla@pasteur.sn (C.T.);
amadoumoustapha.ndoye@pasteur.sn (A.M.N.); aboubacry.gaye@pasteur.sn (A.G.);
ndongo.dia@pasteur.sn (N.D.); mamadou.cisse@pasteur.sn (M.C.);
CheikhTidiane.DIAGNE@pasteur.sn (C.T.D.); mamadou.diop@pasteur.sn (M.D.);
fatoumata.sarr@pasteur.sn (F.D.S.); Marguerite.diatta@pasteur.sn (M.D.); aliou.barry@pasteur.sn (M.A.B.);
ablayseck@gmail.com (A.S.); Philippe.dubrous@pasteur.sn (P.D.); Ousmane.faye@pasteur.sn (O.F.);
Ines.vigan-womas@pasteur.sn (I.V.-W.); cheikh.loucoubar@pasteur.sn (C.L.); Amadou.sall@pasteur.sn (A.A.S.)
Service des Maladies Infectieuses et Tropicales, De Fann University Hospital Center (CNHU FANN),
Dakar BP 5035, Senegal; diallokhardiata@gmail.com (K.D.M.); aissatoulakhe@gmail.com (N.A.L.);
dave11690@gmail.com (D.T.); dayeka10@gmail.com (D.K.); vivich6@gmail.com (V.M.-P.C.D.);
louisefortes@gmail.com (L.F.); maguifall4@gmail.com (N.M.F.); aboubakrbadiane@yahoo.fr (A.S.B.);
seydim@u.washington.edu (M.S.)
Hôpital Principal de Dakar, Dakar BP 220, Senegal; basambasn2000@yahoo.fr (P.S.B.);
mouztaphandm@gmail.com (M.D.)
Centre de Traitement des épidémies de l’Hôpital Dalal Jamm, Dakar BP 19.001, Senegal
Hôpital de Diamnadio, Centre de Traitement des épidémies de l’Hôpital de Diamnadio,
Bargny BP 204, Senegal
Fann University Hospital, Centre de Traitement des épidémies de Touba, Touba 22300, Senegal
Correspondence: fabien.taieb@pasteur.sn
2954. https://doi.org/10.3390/
6
jcm10132954
*
Academic Editors: Philippe Parola,
Abstract: As of today, little data is available on COVID-19 in African countries, where the case
management relied mainly on a treatment by association between hydroxychloroquine (HCQ) and
azithromycin (AZM). This study aimed to understand the main clinical outcomes of COVID-19
hospitalized patients in Senegal from March to October 20202. We described the clinical characteristics
of patients and analysed clinical status (alive and discharged versus hospitalized or died) at 15 days
after Isolation and Treatment Centres (ITC) admission among adult patients who received HCQ plus
AZM and those who did not receive this combination. A total of 926 patients were included in this
analysis. Six hundred seventy-four (674) (72.8%) patients received a combination of HCQ and AZM.
Results showed that the..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit